Abbreviations & Acronyms AML = angiomyolipoma AQP1 = aquaporin 1 BMI = body mass index eGFR = estimated glomerular filtration rate PLIN2 = perilipin 2 RCC = renal cell carcinoma RMB = renal mass biopsy ROC = receiver operating characteristic SD = standard deviation SRM = small renal mass Objective: To evaluate the role of urine aquaporin 1 and perilipin 2 as biomarkers adjunct to renal mass biopsy in guiding the management of patients with small renal masses. Methods: Preoperative aquaporin 1 and perilipin 2 levels in 57 patients with small renal masses undergoing partial nephrectomy were analyzed and compared with postoperative tumor histology. An algorithm was created utilizing aquaporin 1 and perilipin 2 in conjunction with renal mass biopsy. Cut-off values were implemented to maximize biomarker sensitivity and specificity. Renal mass biopsy utilization and intervention were then compared with rates in traditional renal mass biopsy algorithms. Results: All clear cell and papillary renal cell carcinomas were correctly identified and assigned to the treatment path. All benign lesions were correctly sorted to a confirmatory renal mass biopsy path. Two chromophobe masses did not have elevated aquaporin 1 and perilipin 2, and would require renal mass biopsy. Compared with protocols that call for all small renal masses to be biopsied, confirmatory renal mass biopsy could have been safely avoided in 74% of patients with elevated aquaporin 1 and perilipin 2. Compared with protocols that do not utilize renal mass biopsy, surgical intervention would have been avoided in 23% of patients with benign masses. Conclusions: Aquaporin 1 and perilipin 2 possess high sensitivity and specificity for detecting clear cell and papillary renal cell carcinoma. Use of these markers might compliment renal mass biopsy in the characterization of small renal masses.
Introduction
Incidentally found SRMs, defined as stage T1a renal masses ≤4 cm, are detected with greater frequency as a result of more widespread use of modern cross-sectional abdominal imaging. 1, 2 Most solid enhancing masses without fat are RCCs. However, recent literature suggests higher rates of benign pathology in small lesions. 2, 3 Indeed, malignancy directly relates to tumor size. Lesions <1 cm are benign in 46% of cases; lesions <2 cm are benign in 22% of cases. 1 There is a wide range of clinical options in managing patients with a SRM. Some centers routinely biopsy all SRMs, whereas others carry out almost no renal mass biopsies before treatment. Furthermore, depending on patient characteristics and regional practice patterns, providers might recommend active surveillance, image-guided ablation or surgical resection. Among patients who do receive resection, 13-28% have benign pathology. 2, 3 Therefore, non-invasive testing is an important tool in differentiating benign from malignant masses, and can benefit patients by preventing overtreatment of their non-malignant SRMs.
RMB is an adjunct that can differentiate malignant papillary, chromophobe and clear cell RCC from benign lesions, such as oncocytoma and AML. 4 In cases where ablative treatments are performed, RMB is typically carried out concomitantly to provide tissue diagnoses. Currently, some physicians avoid RMB due to patient factors, for fear of false negatives or worry about non-diagnostic results and tumor seeding. However, modern RMB has been proven safe and effective, with sensitivities and specificities reaching 80-92% and 83-100%, respectively. 5, 6 A recently published RMB-based algorithm distinguishes benign from malignant pathology, and directs management between active surveillance and surgical treatment. 7 One disadvantage of RMB, however, is that it is a purely diagnostic procedure. The majority of patients with malignant lesions will likely receive a recommendation for an additional therapeutic procedure.
Urine AQP1 and PLIN2 concentrations are elevated in patients with clear cell and papillary RCC compared with patients with chromophobe RCC, oncocytoma, cystic nephroma, plasmacytoma, hemangioma, AML, non-renal urinary tract cancers, non-cancer renal disease and healthy controls. [8] [9] [10] [11] When used in conjunction, the two markers are able to achieve very high positive and negative predictive values. 11 As a result, AQP1 and PLIN2 have been proposed for use in screening for clear cell and papillary RCC, and for the characterization of imaged renal masses. 12 However, these markers are not elevated in chromophobe RCC and therefore would need to be used in combination with RMB to identify these lesions of low malignant potential. Here, we explore the utility of these biomarkers in conjunction with RMB to characterize SRMs in the least invasive way.
Methods Patients
The Washington University Institutional Review Board approved the present study. Written informed consent was obtained from all patients. Preoperative urine samples were collected between November 2009 and November 2012 from 57 patients with computed tomography or magnetic resonance imaging renal masses ≤4.0 cm. There was pre-surgical concern for RCC in all 57 patients. Post-surgical pathology of the resected masses showed 34 clear cell RCC, eight papillary RCC, two chromophobe RCC, six AML and seven oncocytoma. All of the urine AQP1 and PLIN2 concentrations for these patients have been reported previously. 9, 10 The present dataset is a subset of these patients.
Clinical and pathological data
Demographic and medical histories were recorded including age, sex, past medical history and BMI. Serum creatinine levels were obtained and the eGFR was calculated using the Modification of Diet in Renal Disease equation. 13 Pathology reports provided the histological diagnosis and tumor size.
AQP1 and PLIN2 measurement
Urine biomarker concentrations were determined by western blot and normalized to urinary creatinine concentration, as previously described. [8] [9] [10] Quality control samples evaluated gel-to-gel reproducibility. Results are reported as absorbance units per mg urine creatinine.
Statistical analysis and SRM algorithm
Clinical parameters and urine concentrations were compared among the five tumor subtypes. Analysis was carried out using R statistical software (R Development Core Team, 2010). Descriptive statistics compared continuous variables using the t-test assuming non-equal variance. Categorical variables were compared using the v 2 -test of independence. The Mann-Whitney U-test was used to differentiate AQP1 and PLIN2 among the five subtypes. Two-sided tests were carried out with statistical significance set at the 0.05 level. Based on retrospective data from these cohorts, ROC analysis was used to determine optimum cut-off values each for AQP1 and PLIN2. Two sets of cut-off values for the biomarkers were established to maximize either sensitivity or specificity. A third set of cut-off values were then established to combine the markers into a single test maximizing both sensitivity and specificity. Using these cut-offs, we devised and tested an algorithm using both markers to evaluate the ability to accurately distribute patients with clear cell and papillary RCC into a treatment path, and those with chromophobe RCC, oncocytoma and AML into a biopsy path.
The algorithm was thus constructed so that the combined elevation of urinary AQP1 and PLIN2 would show a true positive test for clear cell and papillary RCC, and a true negative test for chromophobe RCC, AML or oncocytoma. The algorithm would then assign patients with positive results to a treatment path, and those with negative results to a RMB path to confirm benign pathology and find the rare chromophobe RCC. Table 1 lists the patient characteristics. Patients in all groups were statistically similar, with the exception of patients with clear cell and chromophobe RCC having a higher BMI than other patients (P = 0.046). Figure 1 provides the AQP1 and PLIN2 values for all patients. The median AQP1 and PLIN2 values for clear cell and papillary RCC were significantly higher than those of chromophobe RCC, oncocytoma and AML. Combining AQP1 and PLIN2, the sensitivity and specificity were maximized for 100% specificity, sensitivity, positive predictive value and negative predictive value (Fig. 2) . In this combined biomarker algorithm, any patients with AQP1 ≥5 or PLIN2 ≥16 would be assigned to intervention for presumed clear cell or papillary RCC. Patients with AQP1 <5 and PLIN2 <16 would go to RMB. Using these cut-offs, our algorithm would correctly sort patients into the RMB or treatment path in every case. This would result in a 74% reduction in confirmatory biopsies that show clear cell and papillary RCC from conventional RMB algorithms where all SRMs undergo RMB. Also, 23% of patients with benign pathology would have been directed to RMB and avoided resection or ablation. Two patients (3%) with chromophobe RCC did not have elevated AQP1 or PLIN2 and would have undergone RMB.
Results

Discussion
Incremental decreases in renal function raise the risk of hospitalization, cardiovascular events and death.
14 Two publications examined the effects of radical and partial nephrectomy on renal function and overall survival of patients with unanticipated benign renal lesions. Both series found greater postoperative renal function and survival in patients who underwent partial versus radical nephrectomy. 15, 16 Additionally, patients' postoperative eGFR was an independent predictor of cardiac-specific survival, as well as overall survival, with lower eGFR portending less favorable outcomes. 15 These observations provide evidence that renal preservation should be considered when treating patients with SRMs.
The most "nephron-sparing" approach to managing benign SRMs is to diagnose the lesion as benign and avoid unnecessary treatment. Several series document that cross-sectional imaging fails to diagnose benign masses in 13-28% of lesions <4 cm in size.
1-3 A needle-acquired RMB-directed treatment algorithm that detects benign pathology and stratifies management of malignant lesions based on histological characteristics and tumor size has been reported. 7 In that study, preoperative RMB distinguished malignant from benign pathology with 100% accuracy for masses <4 cm. Although this algorithm can be used to prevent the resection of benign renal lesions, there continues to be wide variation in clinical practice. 5, 17 A simple, relatively inexpensive diagnostic urine test to identify which patients are most likely to benefit from RMB could aid in the adoption of RMB, and lead to more widespread adoption and standardization of the evaluation of SRMs.
In 2009, the American Urological Association polled 759 active urologists regarding the management of SRMs. Regarding the use of RMB, 37% of urologists reported that RMB was never ordered in the evaluation of SRMs. Furthermore, 63% occasionally obtained a RMB, whereas just 8% carried out a RMB on >20% of SRMs. 17 Similar practice patterns were observed in the UK; 43% of urologists surveyed never used RMB, and just 23% occasionally used RMB. 5 The risks of false negative results, tumor seeding, intratumor heterogeneity and complications were common reasons for avoiding RMBs. The belief that a RMB would not affect final patient management was also cited as a reason to avoid ordering RMBs. 5 Recent literature, however, does not support these beliefs, and suggests that RMB has a low rate of false negative results and rarely results in severe complications or tumor seeding. 6 Avoiding resection of benign SRMs could significantly decrease patient morbidity, loss of productivity and the risk of developing chronic kidney disease from nephron loss. However, there are hurdles to widespread adoption of a RMB-based treatment algorithm. Factors, such as patient preference or suitability for surgery, might preclude RMB. Furthermore, 72-87% of patients with SRMs have malignant disease and will require some form of further treatment after their biopsy. [1] [2] [3] Biopsy of these masses increases healthcare costs and exposes these patients to some degree of risk with little or no benefit.
The water channel protein, AQP1, has been shown to be involved in multiple cellular mechanisms, including angiogenesis, 18 cell adhesion 19 and cellular proliferation. 20 Although AQP1 is abundantly expressed in the apical membrane of proximal tubule cells, 21 it is also known to be upregulated in lung and brain tumors. 22, 23 In contrast, PLIN2 is involved in lipid metabolism, transport and cellular signaling, 24 and has been shown to be elevated in multiple malignancies that show clear cell pathology, 24, 25 including clear cell RCC. 26 The exact mechanisms by which these markers are passed into the urine are unclear. Although the association of RCC with the proximal tubule provides a mechanism for these markers to be expressed in the urine, it is unclear whether they are secreted or merely shed into the urinary system. However, we have previously shown that elevated AQP1 and PLIN2 are not associated with other urological malignancies, such as prostate or bladder cancer, and that renal tumor size is positively correlated with levels of AQP1 and PLIN2. 8, 9 The high sensitivity and specificity of AQP1 and PLIN2 are promising as a primary means of characterizing renal masses. Within the subset of patients with SRMs, these biomarkers can potentially decrease the need for RMB. Modifying existing algorithms to include urine AQP1 and PLIN2 might prevent the unnecessary resection of benign SRMs, and reduce the number of RMBs required to differentiate benign from malignant lesions.
By combining the two markers, we were able to maximize the sensitivity and specificity of both to detect clear cell and papillary RCC. Patients with AQP1 ≥5 or PLIN2 ≥16 were deemed likely to have clear cell or papillary RCC, and were sorted directly to the treatment path of the algorithm (Fig. 2) . Patients assigned to the treatment path would then be counseled on appropriate management strategies, including observation, ablative therapies and surgical resection. Patients with lower levels would be assigned to the biopsy path. Patients with biopsy-confirmed oncocytoma, AML or other benign lesion would be counseled favoring observation. Importantly, AQP1 and PLIN2 do not detect chromophobe RCC. In the rare cases where the biopsy finds chromophobe RCC not detected by AQP1 and PLIN2, these patients would be counseled on treatment options. Using the combined biomarker and RMB algorithm developed here, RMB would have been avoided in the majority of patients, potentially reducing cost and morbidity in 74% of patients with SRMs.
On a national basis, where RMB has not been widely implemented, the need for differential diagnosis of SRMs is compelling. Approximately 45 000 partial and radical nephrectomies were carried out in the USA alone in the year 2015. 27 It is estimated that 18% of these would involve nephron reduction for a benign tumor (extrapolation of Surveillance, Epidemiology and End Results Program 18 Database). Although utilization of RMB could potentially have prevented unnecessary treatment in these 8000 cases, RMB has not been widely adopted. By adding a non-invasive biomarker test to select patients who would benefit most from a RMB, this algorithm might be able to increase the utilization of these tools in avoiding overtreatment of SRMs. One limitation of the present study was that patients with chromophobe RCC had normal AQP1 and PLIN2 concentrations. 8, 10 Indeed, only one chromophobe RCC was detected when PLIN2 was used at the highest sensitivity. By carrying out a RMB as a second screening tool in patients with normal markers, the algorithm would prevent missed chromophobe RCCs. Fortunately, chromophobe RCC accounts for just 5% for all cases of RCC, and has a better prognosis than clear cell RCC. 28 A multi-institutional review of 291 patients with chromophobe RCC found that just approximately 2% of patients presented with distant metastasis. In their series, 5-and 10-year cancer-specific survival was 93% and 89%, respectively. 29 Among 203 patients with chromophobe RCCs, all 132 patients with lesions <7 cm lacked metastasis at initial presentation. Just two patients with lesions <4 cm in size developed local recurrence or metastasis after primary tumor resection. 28 Furthermore, as previously reported, urinary AQP1 and PLIN2 correspond with tumor size and stage, but not with grade. 30 As a result, aggressive tumor subtypes with a high grade might be missed with the use of these markers alone, and the decision to proceed with active surveillance in the setting of positive urinary markers must be taken with this point in consideration.
Other limitations of our current study were its retrospective nature and the small sample size. Although our results suggest that the sensitivity and specificity of AQP1 and PLIN2 approach 100%, we recognize that this is influenced by our small sample size. Future prospective studies are warranted to validate the algorithm and determine if current cut-off values accurately direct patient care. In addition, current quantifications of AQP1 and PLIN2 are carried out by western blot, which makes large-scale investigation and clinical implementation difficult. Further work will need to be carried out to create scalable ways to quantify these markers.
Despite these considerations, it is clear that urine AQP1 and PLIN2 are elevated in clear cell and papillary RCC subtypes when compared with chromophobe RCC, oncocytoma and AML. By combining the two markers, we can establish a test with high sensitivity and specificity for clear cell and papillary RCCs. Using these non-invasive markers to prescreen patients with SRMs, we might be able to more appropriately select patients for RMB, significantly reducing both the number of surgeries carried out for benign renal masses and the number of renal biopsies required to diagnose malignant renal lesions.
